On May 21, Impact Therapeutics-B (07630.HK) declined 5.77% in regular trading, trading at HK$35.7 per share, with trading volume of approximately HK$5.39 million.

The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange on May 13 at HK$20.10 per share, with its public offering oversubscribed by 2,282.4 times and a ballot rate of just 1.5%. The stock closed its first day at HK$41.86, surging 108.26% above the offer price. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.

Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.

Impact Therapeutics is a commercialization-stage biopharmaceutical company focused on advancing precision anti-cancer therapies based on the synthetic lethality mechanism. Its core product, senaparib, has been approved in China as a first-line maintenance therapy for ovarian cancer and was included in the National Medical Insurance Directory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)